
According to the company, its partnership will educate the gaming community on common dry eye symptoms and introduce over-the-counter options like its Systane brand of eye drops.

According to the company, its partnership will educate the gaming community on common dry eye symptoms and introduce over-the-counter options like its Systane brand of eye drops.

The approval could lead hospitals, universities, corporations and even local governents to enact vaccination mandates.

RightEye Sensorimotor is a new technology designed to greatly improve patient care and increase optometry and ophthalmology practice revenue.

Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients.

The EURETINA 2021 Virtual Meeting is scheduled for Sept. 9 to 12, and retina specialists eagerly await the showcase of cutting-edge scientific developments.

Science fiction is quickly becoming science fact as a team of German scientists has developed a small, lab-grown brain cell cluster that developed fundamental eye structures.

A survey by Health Union sheds light on the issues patients are facing and can help ophthalmologists map out dry eye disease treatment strategies.

The American Society of Retina Specialists is gearing up for its 39th annual scientific meeting Oct. 8-12 at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

A new study reveals that children of mothers with diabetes during pregnancy have an increased risk of eye problems.

Michael Rivers, MD, discusses how Modernizing Medicine's latest updates to its electronic health records EMA® system benefits both ophthalmologists and optometrists.

Scientists have developed a new approach that is less complex and does not require extracting the genetic RNA material of the virus.

The Academy has stepped up to speak out against the use of untested biosimilars in the eyes of patients amid a disruption in the drug supply chain.

Aequus Pharmaceuticals, reVision Therapeutics announced this week that they will collaborate to develop a therapy for Stargardt disease.

Oxurion is currently recruiting patients for the Phase 2 clinical study of THR-687 in DME.

The company shared data from its two-year Phase III KITE trial and the one-year phase III KINGFISHER trial.

Tool for quantifying measures may predict outcomes for patients.


Substantial weight loss can help patients’ eye health, study results show.

The Research to Prevent Blindness (RPB), the Association of University Professors of Ophthalmology (AUPO) and an anonymous donor have recognized Donald Zack, MD, PhD, for ground-breaking contributions to the field of vision research.


According to Oculus, its Myopia Master saves space and can be mounted on a workstation or an ophthalmic table. The software is operated directly via an inbuilt display.

The company is evaluating topical cyclosporine to treat the signs and symptoms of dry eye disease.

According to the Refractive Surgery Council, patients continue to have a high level of interest in laser vision correction procedures.

Taking control of a practice’s future with investment, creative thinking

pVerify's Vision Benefits API allows front-office staff to handle vision eligibility verifications seamlessly in their own EHR.

Most patients with allergic disorder are children, adolescents, or young adults.

Llama nanobodies may be key to beating COVID-19 variants.

Heru Inc., announced Thursday that it has partnered with Vision Source on the commercial availability launch of re:Vive, a wearable diagnostics and visual field application.

Outlook Therapeutics has reported positive efficacy and safety data from Phase 3 NORSE TWO trial of bevacizumab-vikg.

The organization hopes to help 1 billion people worldwide, committing the international community to improve vision for 1.1 billion people living with preventable vision loss by 2030.